Key statistics
On Friday, Hansa Biopharma AB (HNSA:STO) closed at 29.48, 50.56% above the 52 week low of 19.58 set on Apr 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 29.50 |
|---|---|
| High | 30.20 |
| Low | 28.58 |
| Bid | 29.48 |
| Offer | 29.48 |
| Previous close | 29.12 |
| Average volume | 371.16k |
|---|---|
| Shares outstanding | 101.76m |
| Free float | 48.58m |
| P/E (TTM) | -- |
| Market cap | 3.00bn SEK |
| EPS (TTM) | -6.44 SEK |
Data delayed at least 15 minutes, as of Mar 13 2026 17:00 BST.
More ▼
- PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026
- PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026
- Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA
- Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA
- Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
- Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results
- Hansa Biopharma has won the 2025 SwedenBIO Award
- Hansa Biopharma has won the 2025 SwedenBIO Award
- Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
- Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
More ▼
